论文部分内容阅读
采用高效液相色谱法测定了抗心律失常药劳卡胺（Ｌｏｒ）及其活性代谢产物去甲劳卡胺（ＮＬ）血药浓度。线性范围分别为０·０２５～０·８ｍｇ·Ｌ－１和０．０３１～ｌｍｇ·Ｌ－１，最低检测浓度均为０．００５ｍｇ·Ｌ－１，方法回收率分别为９８．０５％±４．ＺＩ％和９８．７０％±６．８９％，两者天内和天间变异系数皆小于５％。对６例室性早搏（ＶＰＣｓ）患者ＰｏＬｏｒ１５０ｍｇ·ｄ－１或３００ｍｇ·ｄ－１２ｗｋ血药浓度测定及临床观察，结果表明：连续给药１ｗｋ，Ｌｏｒ及ＮＬ血药浓度基本达稳态水平；Ｌｏｒ连续ｐｏ给药，其活性代谢产物ＮＬ在血液中蓄积，达到或甚至超过其母体药物浓度；４例有效者Ｌｏｒ及ＮＬ稳态血浓均大于０．１ｍｇ·Ｌ－１。该ＨＰＬＣ法稳定可靠，适于临床分析。
The plasma concentration of antiarrhythmic drug Lor and its active metabolite demethylcalacarine (NL) was determined by high performance liquid chromatography (HPLC). The linear range was 0.025-0.8 mg · L-1 and 0.031-1 mg · L-1, respectively, and the lowest detection concentration was 0.005 mg · L-1. The recoveries were 98.05% ± 4 . ZI% and 98.70% ± 6.89% respectively, both of them were less than 5%. The plasma concentrations of PoLor 150 mg · d-1 or 300 mg · d-12wk in 6 patients with ventricular premature beats (VPCs) were measured. The results showed that the plasma concentrations of Lor and NL reached steady state at 1 wk, Continuous po administration, the active metabolite NL accumulation in the blood, reaching or even exceeding the concentration of its parent drug; 4 cases of effective Lor and NL steady-state blood concentrations were greater than 0.1mg · L-1. The HPLC method is stable and suitable for clinical analysis.